Becton Dickinson (BDX) ended at a closing price of $217.14 on February 9, 2018. The stock hit its 52-week high of $248.39 on January 29, 2018. As of February 12, 2018, BD stock had risen ~17.2% since April 24, 2017, when the company reported its 52-week low of $175.66. Currently, the stock is trading below its 50-day moving average of $227.98 and higher than its 200-day moving average of $211.59.
On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations. For details on the earnings results, read Becton Dickinson’s Fiscal 1Q18 Results Beat Analyst Estimates. BD stock registered a rise of ~1.2%. However, since BD stock registered its 52-week high on January 29, 2018, the stock has declined by ~8.5%. The stock has been affected by the global stock market meltdown. Over the last one month, BD stock registered returns of -3.3%. In contrast, the stock’s six-month return stands at ~9.5%.
Over the last one year, BD stock has returned ~21.9% to investors. In comparison, the SPDR S&P 500 (SPY) and the Health Care Select Sector SPDR ETF (XLV) have posted one-year returns of 13.1% and 14.2%, respectively, as of February 12, 2018. Becton Dickinson performed better than the broader market as well as the healthcare industry over the past one year. However, BD stock’s performance was in line with the broader US medical technology sector, represented by the iShares U.S. Medical Devices ETF (IHI), which returned ~21.4% over the last 12 months.
As of February 12, 2018, peers Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO), and Medtronic (MDT) registered 12-month returns of 33.7%, 29.2%, and 4.3%, respectively. Peers Abbott Laboratories and Thermo Fisher Scientific largely outperformed BD’s stock performance in the last 12 months.